Abcam, ab321811, Anti-ACSL3 antibody [EPR29199-39]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal ACSL3 antibody. Suitable for WB and reacts with Human, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR29199-39,
Isotype:IgG,
Carrier free:No,
Reacts with:Human, Mouse,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ACSL3 protein also known as Acyl-CoA synthetase long-chain family member 3 plays a central role in lipid metabolism. It is an enzyme with a mass of approximately 79 kDa that activates long-chain fatty acids by converting them into acyl-CoA thioesters. This process is critical for their subsequent use in metabolic pathways. ACSL3 expression occurs mainly in the liver adipose tissue and brain tissues involved in energy balance and storage. By catalyzing the initial step in the fatty acid metabolic pathway ACSL3 influences lipid biosynthesis and degradation.
Biological function summary
ACSL3 contributes to cellular processes involving lipid synthesis and energy production. It functions as part of a larger lipid metabolic framework where it facilitates the incorporation of fatty acids into complex lipids like phospholipids and triglycerides. Though not a member of a molecular complex in terms of protein structure its activity complements other enzymes involved in lipid metabolism indicating an indirect association with lipid-binding proteins and transport mechanisms. The metabolic activity of ACSL3 therefore plays a significant role in maintaining cell membrane integrity and energy balance.
Pathways
ACSL3 integrates into the peroxisome proliferator-activated receptor (PPAR) signaling and fatty acid metabolism pathways. These pathways coordinate the regulation and utilization of lipids for energy storage and consumption. The ACSL3 protein interacts with proteins such as PPARα and PPARγ which are transcription factors that regulate gene expression associated with lipid metabolism. Through these interactions ACSL3 affects lipid metabolism at a genomic level promoting the adaptive responses necessary for cellular energy requirements.
ACSL3 association with metabolic conditions like obesity and non-alcoholic fatty liver disease (NAFLD) is evident. In obesity ACSL3 expression may alter lipid metabolism contributing to excess fat accumulation and energy imbalance. Additionally elevated ACSL3 levels in the liver could be linked to NAFLD enhancing lipid storage and steatosis. The protein interacts indirectly with other players in metabolic diseases such as SREBP-1c and AMPK which are critical regulators of lipid homeostasis and energy balance in cells. These connections suggest that ACSL3 is a potential target for therapeutic interventions in metabolic disorders.